TGFK-09SD

TGFK-09SD
Clinical data
Other namesTGFK09SD
Routes of
administration		Oral[1]
Drug classSerotonin 5-HT1A receptor agonist
ATC code
  • None

TGFK-09SD, or TGFK09SD, is a serotonin 5-HT1A receptor agonist which is or was under development for the treatment of female sexual dysfunction but was never marketed.[1][2] It is taken orally.[1] The drug was developed by Fabre-Kramer Pharmaceuticals.[1] As of January 2016, it is in phase 2 clinical trials.[1] There have been no further updates on the development of the drug since then.[1] The chemical structure of TGFK-09SD does not yet appear to have been disclosed.[1]

See also

References

  1. ^ a b c d e f g "TGFK 09SD". AdisInsight. 8 January 2016. Retrieved 27 January 2026.
  2. ^ "Details of the Drug-Related molecule(s) Interaction Atlas". DrugMAP. 1 April 2024. Retrieved 27 January 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.